To Study the Efficacy of FF/VI Combination in Adult Asthma Patients

Background: Long-acting beta2-agonists (LABA) and inhaled corticosteroids require twice daily administration for effective treatment of bronchial asthma.This study aims to study the efficacy of fluticasone furoate/vilanterol (FF/VI) ICS/Ultra-LABA once-daily combination therapy in patients with bronchial asthma.Materials and methods: This prospective observational study included 120 spirometry-diagnosed patients of bronchial asthma who were given FF/VI combination therapy and underwent follow-up at 2, 4, and 8 weeks of therapy.Patients were assessed during the follow-up period for the efficacy of therapy based on spirometric values.Results: In the present study 61.7% were females and 38.3% were males.The commonest presenting symptom was cough present in 95% of patients followed by wheezing which was seen in 93.3% of patients and shortness of breath in 89.17% of patients.At 8 weeks of continuous therapy, only 5% of patients had a cough, 8.33% had wheezing and only 2.5% complained of shortness of breath.Forced expiratory volume (FEV) in one second (FEV1) at baseline, was 56.60 1.26, and by the end of 8 weeks, it increased to 90.36 11.38.Forced vital capacity (FVC) at baseline was 64.83 12.63 and it increased to 91.8 1035 at 8 weeks.Forced expiratory volume in one second (FEV1)/FVC at baseline was 63.31 4.90 and it increased to 74.59 3.19 at 8 weeks.Forced expiratory flow (FEF) 25-75% at baseline was 35.42 14.74, and at 8 weeks of continuous therapy, it increased to 76.35 8.85 and all these values were statistically significant (p < 0.05).The spirometric mean values were highly significant (p < 0.001) in between 2-4 weeks and 4-8 weeks.Conclusion: Therapeutic continuity of FF/VI combination therapy is significantly effective in improving both symptoms and spirometric values in bronchial asthma patients.The safety profile and improvements in lung function irrespective of dosing time (morning or evening) strongly emphasize strict adherence to continuous once-daily use of the inhaler FF/VI to fully reverse the condition.